Thursday, January 04, 2007 7:30:00 AM PDT | VentureDeal Staff
NATICK, MA -- Boston Scientific Corporation
(NYSE: BSX) announced that it had acquired EndoTex
Interventional Systems, following the FDA approval of EndoTex' NexStent (R)
Carotid Stent System that was studied in a trial with Boston Scientifics
FilterWire Embolic Protection System.
The NexStent system is a "laser-cut, nitinol stent with rolled sheet design
that enables one stent size to adapt to multiple diameters in tapered or
non-tapered vessel systems."
Terms of the transaction were not disclosed.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
© 2016 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.